




CLAIMS

1. Use of a compound of Formula (**V**) or a pharmaceutically acceptable salt or solvate thereof in the manufacture of a medicament for the treatment of a neurogenerative condition and/or for neuroprotection in a subject having said neurogenerative condition, wherein the compound is of Formula (**V**):



(**V**),










wherein:

- Ring A is  ;
- E is  ; and
- Y is  or  ,


and wherein said neurogenerative condition is multiple sclerosis.

2. The use according to claim 1, wherein the subject exhibits an aberrant level of a biomarker associated with the neurodegenerative condition prior to the treatment.


3. The use according to claim 1 or 2, wherein the compound is


,

,

,

,

,

,

,

or

.

4. The use according to any one of claims 1 to 3, wherein the compound is


or a pharmaceutically acceptable salt or solvate thereof.

5. The use according to any one of claims 1 to 4, wherein the compound is


.

6. The use according to claim 2, wherein the biomarker is Nurr1.

7. The use according to claim 2 or 6, wherein the aberrant level of the biomarker associated with the neurodegenerative condition is downregulated Nurr1.

8. The use according to any one of claims 1 to 7, wherein disability associated with the multiple sclerosis is acquired through progression independent of relapse activity (PIRA).

9. The use according to any one of claims 1 to 7, wherein the multiple sclerosis comprises brain atrophy induced by the multiple sclerosis.


10. The use according to any one of claims 1 to 7, wherein the multiple sclerosis is non-inflammatory multiple sclerosis worsening.

11. The use according to any one of claims 1 to 10, wherein the neuroprotection is slowing or preventing loss of neurons induced by the multiple sclerosis.


12. The use according to any one of claims 1 to 10, wherein the neuroprotection is slowing or preventing loss of dopaminergic neurons induced by the multiple sclerosis.

13. The use according to any one of claims 1 to 12, wherein said multiple sclerosis is characterized by progression independent of relapse activity (PIRA).

14. The use according to claim 13, wherein the compound is



or a pharmaceutically acceptable salt or solvate thereof, preferably



.

15. The use according to any one of claims 1 to 13, wherein the medicament comprises about 5 mg to about 100 mg of the compound.

16. The use according to any one of claims 1 to 15, wherein the medicament is formulated for oral administration of a solid dosage form.

17. The use according to any one of claims 1 to 16, wherein said treatment is to prevent or slow disease progression and secondary injuries by halting or at least slowing (mitigate) the loss of neurons.

18. The use according to any one of claims 1 to 17, wherein the subject has no evidence of relapse for 24 months.

19. The use according to any one of claims 1 to 18, wherein the multiple sclerosis is progressive multiple sclerosis (PMS).

20. The use according to claim 19, wherein the PMS is characterized by few or no active lesions.

21. The use according to any one of claims 1 to 18, wherein the multiple sclerosis is primary progressive multiple sclerosis (PPMS).

22. The use according to any one of claims 1 to 18, wherein the multiple sclerosis is non-active secondary progressive multiple sclerosis (n-aSPMS).

23. The use according to claim 22, wherein the n-aSPMS is characterized by no lesions for 12 months.

24. The use according to any one of claims 1 to 18, wherein the multiple sclerosis is active secondary progressive multiple sclerosis (a-SPMS).